COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,891 Articles (22,568 medRxiv, 8,323 bioRxiv)

Most recent first Previous |  Page 423: Articles 4221-4230  | Next

Molecular Neuropathology and Cerebrospinal Fluid Diagnostic Biomarkers of SARS-Cov2 Infection in Central Nervous System: A Scoping Review Protocol
Kyaruzi, V. M., Mduma, E., Bandyopadhyay, S., Nyalundja, A. D., Kamabu, K., Atron, B., Nathan, M., Itodo Daniel, J. O., Elamin, Y. Z., Marwa, B. B., Msemo, R., Naeem, A., jean de Dieu, T. M., Kumar, T. S., Tazoah, N. B., Chiazo, U. F., David, S. O., Nsavyimana, Y. J., Bureta, C. A., Rutabasibwa, N., Mchome, L. L., Shimber, E. T., Tirsit, A., Mfinanga, S., Hassen, G. W., Abdellaziz, O., Mwakigonja, A.
10.1101/2023.03.17.23287405 — Posted: 2023-03-17
A general computational design strategy for stabilizing viral class I fusion proteins
Gonzalez, K. J., Huang, J., Criado, M. F., Banerjee, A., Tompkins, S. M., Mousa, J. J., Strauch, E. M.
10.1101/2023.03.16.532924 — Posted: 2023-03-17
How have mathematical models contributed to understanding the transmission and control of SARS-CoV-2 in healthcare settings? A systematic search and review
Smith, D. R. M., Chervet, S., Pinettes, T., Shirreff, G., Jijon, S., Oodally, A., Jean, K., Opatowski, L., Kerneis, S., Temime, L.
10.1101/2023.03.17.23287403 — Posted: 2023-03-17
Antibodies generated in vitro and in vivo elucidate design of a thermostable ADDomer COVID-19 nasal nanoparticle vaccine
Buzas, D., Bunzel, H. A., Staufer, O., Milodowski, E., Edmonds, G., Vidana Matteo, b., Berger Schaffitzel, C., Yadav, S., Gupta, K., Fletcher, C., Kavanagh Williamson, M., Harrison, A., Borucu, U., Capin, J., Francis, O., Balchin, G., Hall, S., Vivoli Vega, M., Durbesson, F., Vincentelli, R., Roe, J., Wooldridge, L., Burt, R., Anderson, R., Mulholland, A. J., Hare, J., Bailey, M., Davidson, A., Finn, A., Morgan, D., Mann, J., SPatz, J., Garzoni, F., Bufton, J., Berger, I.
10.1101/2023.03.17.533092 — Posted: 2023-03-17
Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022 (bivalent vaccine) booster campaigns: a prospective test negative case-control study
Chatzilena, A., Hyams, C., Challen, R., Marlow, R., King, J., Adegbite, D., Kinney, J., Clout, M., Maskell, N., Oliver, J., Finn, A., Danon, L., The AvonCAP Research Group
10.1101/2023.03.16.23287360 — Posted: 2023-03-17
Serial SARS-CoV-2 antibody titers in vaccinated dialysis patients: prevalence of unrecognized infection and duration of seroresponse
Hsu, C. M., Weiner, D. E., Manley, H. J., Miskulin, D., Ladik, V., Frament, J., Argyropoulos, C., Abreo, K., Chin, A., Gladish, R., Salman, L., Johnson, D., Lacson, E. K.
10.1101/2023.03.16.23287322 — Posted: 2023-03-17
Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: phylogenetic analysis and intervention scenarios
Reichmuth, M., Hodcroft, E. B., Althaus, C. L.
10.1101/2023.03.13.23287198 — Posted: 2023-03-17
Modelling the impact of hybrid immunity on future COVID-19 epidemic waves
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M. J., McVernon, J., Mueller, I., Walker, C. R., Baker, C. M.
10.1101/2023.03.12.23287174 — Posted: 2023-03-17
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
Moser, C. B., Chew, K. W., Giganti, M. J., Li, J. Z., Aga, E., Ritz, J., Greninger, A., Javan, A. C., Bender Ignacio, R. A., Daar, E. S., Wohl, D. A., Currier, J. S., Eron, J. J., Smith, D. M., Hughes, M. D.
10.1101/2023.03.13.23287208 — Posted: 2023-03-17
Quantitative LC-MS study of compounds found predictive of COVID-19 severity and outcome
Roberts, I., Wright Muelas, M., Taylor, J. M., Davison, A. S., Winder, C. L., Goodacre, R., Kell, D. B.
10.1101/2023.03.17.23287401 — Posted: 2023-03-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).